214 related articles for article (PubMed ID: 27634910)
1. Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis.
Kim SJ; Shin HT; Lee HO; Kim NK; Yun JW; Hwang JH; Kim K; Park WY
Oncotarget; 2016 Oct; 7(42):68350-68359. PubMed ID: 27634910
[TBL] [Abstract][Full Text] [Related]
2. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.
Lionetti M; Barbieri M; Todoerti K; Agnelli L; Marzorati S; Fabris S; Ciceri G; Galletti S; Milesi G; Manzoni M; Mazzoni M; Greco A; Tonon G; Musto P; Baldini L; Neri A
Oncotarget; 2015 Sep; 6(27):24205-17. PubMed ID: 26090869
[TBL] [Abstract][Full Text] [Related]
3. Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma.
Perroud C; Thurian D; Andres M; Künzi A; Wiedemann G; Zeerleder S; Bacher U; Pabst T; Banz Y; Porret N; Rebmann E
Hematol Oncol; 2023 Dec; 41(5):912-921. PubMed ID: 37452600
[TBL] [Abstract][Full Text] [Related]
4. Activating
Shirazi F; Jones RJ; Singh RK; Zou J; Kuiatse I; Berkova Z; Wang H; Lee HC; Hong S; Dick L; Chattopadhyay N; Orlowski RZ
Proc Natl Acad Sci U S A; 2020 Aug; 117(33):20004-20014. PubMed ID: 32747568
[No Abstract] [Full Text] [Related]
5. Challenging a dogma: co-mutations exist in MAPK pathway genes in colorectal cancer.
Grellety T; Gros A; Pedeutour F; Merlio JP; Duranton-Tanneur V; Italiano A; Soubeyran I
Virchows Arch; 2016 Oct; 469(4):459-64. PubMed ID: 27401719
[TBL] [Abstract][Full Text] [Related]
6. The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma.
Stein CK; Pawlyn C; Chavan S; Rasche L; Weinhold N; Corken A; Buros A; Sonneveld P; Jackson GH; Landgren O; Mughal T; He J; Barlogie B; Bergsagel PL; Davies FE; Walker BA; Morgan GJ
Oncotarget; 2017 Apr; 8(17):27854-27867. PubMed ID: 28427158
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
[TBL] [Abstract][Full Text] [Related]
8. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
[TBL] [Abstract][Full Text] [Related]
9. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
10. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.
Kortüm KM; Mai EK; Hanafiah NH; Shi CX; Zhu YX; Bruins L; Barrio S; Jedlowski P; Merz M; Xu J; Stewart RA; Andrulis M; Jauch A; Hillengass J; Goldschmidt H; Bergsagel PL; Braggio E; Stewart AK; Raab MS
Blood; 2016 Sep; 128(9):1226-33. PubMed ID: 27458004
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.
Kis O; Kaedbey R; Chow S; Danesh A; Dowar M; Li T; Li Z; Liu J; Mansour M; Masih-Khan E; Zhang T; Bratman SV; Oza AM; Kamel-Reid S; Trudel S; Pugh TJ
Nat Commun; 2017 May; 8():15086. PubMed ID: 28492226
[TBL] [Abstract][Full Text] [Related]
12. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T
Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768
[TBL] [Abstract][Full Text] [Related]
13. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
[TBL] [Abstract][Full Text] [Related]
14. [Chromosomal abnormalities and clonal evolution in multiple myeloma].
Ishida T
Rinsho Ketsueki; 2014 Oct; 55(10):2036-45. PubMed ID: 25297769
[No Abstract] [Full Text] [Related]
15. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
Mulligan G; Lichter DI; Di Bacco A; Blakemore SJ; Berger A; Koenig E; Bernard H; Trepicchio W; Li B; Neuwirth R; Chattopadhyay N; Bolen JB; Dorner AJ; van de Velde H; Ricci D; Jagannath S; Berenson JR; Richardson PG; Stadtmauer EA; Orlowski RZ; Lonial S; Anderson KC; Sonneveld P; San Miguel JF; Esseltine DL; Schu M
Blood; 2014 Jan; 123(5):632-9. PubMed ID: 24335104
[TBL] [Abstract][Full Text] [Related]
16. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
[TBL] [Abstract][Full Text] [Related]
17. Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis.
Li N; Lin P; Zuo Z; You MJ; Shuai W; Orlowski R; Manasanch EE; Li S; Xu J; Garces S; Jelloul FZ; Tang Z; Wang W; Medeiros LJ; Yin CC
Cancer Med; 2023 Jul; 12(13):14293-14304. PubMed ID: 37212518
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
19. Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice.
Abdelraouf F; Sharp A; Maurya M; Mair D; Wotherspoon A; Leary A; Gonzalez de Castro D; Bhosle J; Nassef A; Gaafar T; Popat S; Yap TA; O'Brien M
BMC Res Notes; 2015 Nov; 8():688. PubMed ID: 26581482
[TBL] [Abstract][Full Text] [Related]
20. Genomic profiling in amyloid light-chain amyloidosis reveals mutation profiles associated with overall survival.
Huang XF; Jian S; Lu JL; Shen KN; Feng J; Zhang CL; Tian Z; Wang JL; Lei WJ; Cao XX; Zhou DB; Liang ZY; Li J
Amyloid; 2020 Mar; 27(1):36-44. PubMed ID: 31635489
[No Abstract] [Full Text] [Related]
[Next] [New Search]
